Projecting future drug expenditures--2006.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  American Journal of Health-System Pharmacy

• Publication date

  2006-01-15

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.2146/AJHP050446PMID 16390926
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage

  2007cited by this paper
• Potential Savings From Substituting Generic Drugs for Brand-Name Drugs: Medical Expenditure Panel Survey, 1997-2000

  2006cited by this paper
• Generic manufacturers riding a wave of market consolidation

  2005cited by this paper
• Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis.

  2005cited by this paper
• Changing dynamics in the pharmaceutical supply chain: a GPO perspective.

  2005cited by this paper
• Future of COX2 inhibitors

  2005cited by this paper
• Tracking health care costs: declining growth trend pauses in 2004.

  2005cited by this paper
• Projecting future drug expenditures--2005.

  2005cited by this paper
• Recombinant activated factor VII for acute intracerebral hemorrhage.

  2005cited by this paper
• U.S. health spending projections for 2004-2014.

  2005cited by this paper
• Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials.

  2005cited by this paper
• Indian generics companies go on spending spree

  2005cited by this paper
• Nesiritide - not verified.

  2005cited by this paper
• Biogenerics at the gate waiting for the FDA to act

  2005cited by this paper
• First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.

  2005cited by this paper
• Neuroimaging heats up

  2005cited by this paper
• Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease.

  2005cited by this paper
• What ails the FDA?

  2005cited by this paper
• Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.

  2005cited by this paper
• New economics of the pharmaceutical supply chain.

  2005cited by this paper
• Direct thrombin inhibitors.

  2005cited by this paper
• Risk of Worsening Renal Function With Nesiritide in Patients With Acutely Decompensated Heart Failure

  2005cited by this paper
• Medication counseling in Zimbabwe.

  2004cited by this paper
• Price hikes for generic injectable antibiotics.

  2004cited by this paper
• The Medicare Prescription Drug, Improvement, and Modernization Act of 2003: implications for health-system pharmacy.

  2004cited by this paper
• "Me-too" products--friend or foe?

  2004cited by this paper
• Projecting future drug expenditures--2004.

  2004cited by this paper
• Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control.

  2003cited by this paper
• Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections.

  2003cited by this paper
• The outlook for hospital spending.

  2003cited by this paper
• Natalizumab for active Crohn's disease.

  2003cited by this paper
• Helping to manage the high cost of rare diseases.

  2003cited by this paper
• Responding to the Immunoglobulin Shortage: A Case Study

  2002cited by this paper

• Impact of connected dispensing technology with advanced analytics in a multicenter health system

  2024cites this paper
• ASHP Guidelines on Medication Cost Management Strategies for Hospitals and Health Systems

  2019cites this paper
• The role of uncertainty in supply chains under dynamic modeling

  2017cites this paper
• The role of uncertainty in supply chains under dynamic modeling

  2016cites this paper
• Development of MY-DRG casemix pharmacy service weights in UKM Medical Centre in Malaysia

  2015cites this paper
• Accuracy of prescription drug expenditure forecasts published in the American Journal of Health-System Pharmacy

  2015cites this paper
• Implementation of Pharmaceutical Practice Guidelines by a Project Model Based

  2015cites this paper
• Accuracy of annual prescription drug expenditure forecasts in AJHP.

  2015cites this paper
• The Utility of Procalcitonin as a Biomarker to Limit the Duration of Antibiotic Therapy in Adult Sepsis Patients

  2014cites this paper
• Prescribing behavior on a clinical department leadership level in public hospitals

  2013cites this paper
• Projecting future drug expenditures--2012.

  2012cites this paper
• In‐Hospital Databases

  2012cites this paper
• Projecting future drug expenditures: 2011.

  2011cites this paper
• [Comparative profile of medications at the "Hospital Infantil de México" and the "Instituto Mexicano del Seguro Social"].

  2010cites this paper
• Projecting future drug expenditures--2010.

  2010cites this paper
• Projecting future drug expenditures--2009.

  2009cites this paper
• Factors associated with the market availability of systemic anti-infective products in Thailand (no. 743)

  2009cites this paper
• Priority setting for expensive biopharmaceuticals : an analysis of six drug case studies.

  2009cites this paper
• Trends in pharmaceutical expenditures: the impact on drug benefit design.

  2008cites this paper
• The Impact of Methodological Approach on Cost Findings in Comparison of Epoetin Alfa with Darbepoetin Alfa

  2008cites this paper
• Effect of racial differences on ability to afford prescription medications.

  2008cites this paper
• Projecting future drug expenditures--2008.

  2008cites this paper
• Scientific and legal viability of follow-on protein drugs.

  2008cites this paper
• Identification of Drug Cost Reduction Opportunities in A University Hospital in Saudi Arabia

  2008cites this paper
• Variation in the cost of medications for the treatment of colorectal cancer.

  2008cites this paper
• Off-Label Prescribing of Erythropoiesis-Stimulating Proteins in US Hospitals

  2007cites this paper
• Voluntary Physician Switching by Human Immunodeficiency Virus-Infected Individuals: A National Study of Patient, Physician, and Organizational Factors

  2007cites this paper
• Cost of cancer care: issues and implications.

  2007cites this paper
• Generics—Present and Future

  2007cites this paper
• Study on variations in price of prescription medicines in Thailand.

  2007cites this paper
• Selective Therapeutic Interchange Practices in Ontario Acute Care Hospitals

  2007cites this paper
• Projecting future drug expenditures--2007.

  2007cites this paper
• Industrin överdriver kostnaderna för utveckling av nya läkemedel

  2006cites this paper
• Inpatient Oncology Length of Stay and Hospital Costs: Implications for Rising Inpatient Expenditures

  2006cites this paper
• Implementing guidelines for the institutional use of factor VIIa (recombinant): a multidisciplinary solution.

  2006cites this paper
• Biotechnology in Cuba: 20 years of scientific, social and economic progress

  2006cites this paper
• Medication costs in Wisconsin Medicaid: Waste not, want not?

  2006cites this paper